Diabetes ? Insulin tabletten statt Insulin spritzen = Blockbuster - 500 Beiträge pro Seite

[BrauchGeld]

Es sind nur wenige Unternehmen die in diesem bereich forschen dazu gehört Apollo Life Science (AOP.AX) die einen ersten erfolg für sich verbuchen können .
Laut unternehmen würden einige Big Pharmas schon interesse zeigen .
Die Aktie ist zwar spekulativ aber für unter 50 mio€ marktkap ist das potential gewaltig.



Homepage:
http://www.apollolifesciences.com/

Successful Phase I oral insulin toxicity result (1.Feb 2007)
http://www.apollolifesciences.com/Uploads/ASX/ASX_66.pdf

Investor Presentation February 2007
http://www.apollolifesciences.com/Uploads/ASX/ASX_75.pdf

Oral insulin: clinical human trials, here we come...
http://www.apollolifesciences.com/Newsarticles/News05OralIns…





Professor Paul
Zimmet AO
Head of
International Diabetes Institute, Melbourne

"The data that I have seen so far makes this one of the most forward looking and best prospects of an oral insulin"

[BrauchGeld]

Am 4. april endet die aktuelle K.E. danach dürfte es wieder aufwärts gehen ,Apollo ist meiner meinung nach eine äusserst interessante aktie .


Company News:
http://au.finance.yahoo.com/q/aca?s=AOP.AX

Ferrets Stock to Watch: APOLLO LIFE SCIENCES LTD
Friday, February 23, 2007

BREAKTHROUGH IN ORAL DELIVERY FOR ARTHRITIS SUFFERERS

Sydney - Friday - February 23: (RWE Aust Business News)
*******************************************************

OVERVIEW
********

Ferret has kept a watchful eye on Apollo Life Sciences (ASX:AOP)
over the past six months in the hope that the biotech researcher makes a
major breakthrough.

This week the company produced a report that looks seriously
encouraging in relation to arthritis.

Apollo has successfully reduced inflammation with oral doses of
Tumour Necrosis Factor (TNF) blocker.

The preclinical studies used Oradel, Apollo's technology for oral
delivery of large water-soluble proteins, including insulin and
antibodies.

The company says that like people with diabetes, patients
prescribed TNF blockers for inflammation associated with rheumatoid
arthritis currently have no alternative to injections.

Apollo is aiming for the global market for TNF blockers estimated
to be almost $13 billion in 2006, and growing at more than 30 per cent a
year.

The statement to the ASX disclosed results from the preclinical
studies, and indicated that oral doses of Apollo TNF blocker ALS-00T2
using Oradel significantly reduced inflammation to a comparable degree to
subcutaneous injection of the molecule.

In the studies, inflammation was induced using carrageenan.

Solutions were administered daily, either by subcutaneous
injection or orally and swelling was measured twice daily.

The carrageenan model is classically used in the development of
non-steroidal anti-inflammatory drugs.

The studies showed that the Oradel technology can be used to
deliver an antibody-sized drug, such as Apollo ALS-00T2, in a more
convenient form than is now possible.

Large proteins and antibody-based drugs are a growing class of
therapeutics that still need to be injected because they are usually
destroyed by the stomach's digestive acids.

A second major application for the Oradel platform is currently
in development for oral insulin.

Oradel protects the protein in the stomach and makes sure the
drug travels across the stomach wall to where it can work, said Apollo's
director of science, Dr Greg Russell-Jones.

"This is a breakthrough," he declared.

"We understand no-one else has been able to deliver antibodies
and large proteins such as TNF blockers in tablet form."

These latest studies show that Oradel can be used to deliver a
wide range of the drugs already in the global protein therapeutics
market.

Antibodies are the fastest growing segment of that market and
were estimated to represent a quarter of it in 2005.

The company said most people will prefer tablets to injections
for these drugs, so there is a ready-made market for Oradel products.

SHARE PRICE MOVEMENTS
*********************

Shares of Apollo yesterday slipped 2.5c to 46c in reaction to
yesterday's climbed to 52c following its latest research report. Rolling
high for the year is 85c and low 30c. The company has 89.4 million shares
on issue with a market cap of $46.4 million.

At the beginning of February, Apollo Life Sciences announced that
the final report confirms the success of its oral insulin in Phase 1
toxicology trials.

Apollo's oral insulin consists of Oradel, loaded with generic
insulin.

The treatment proved safe at both low and high doses.

The toxicology study was designed to test the safety of Apollo's
oral insulin for people with diabetes.

Oradel insulin was administered daily to two animal species for
14 days, followed by a 14-day recovery period.

Control groups received treatment with the vehicle alone.

The key findings are that Oradel insulin caused no toxic effects
or treatment-related changes in body weights, food consumption, blood
analysis, urinalysis, gross necroscopy or histopathology.

"These favourable results provide strong supporting safety data
for taking our oral insulin to Phase 1 human clinical trials, which we
expect to undertake in the coming months," Dr Russell-Jones said.

Diabetes is responsible for approximately four million deaths
worldwide every year.

It is estimated that there are now 246 million people with
diabetes, growing to 380 million by 2025.

A recent United Nations resolution calling on all countries to
develop national policies for the prevention, treatment and care of
diabetes acknowledges global concern at the prevalence of diabetes.

"Our innovative oral insulin could mean the end of needles for
many people with diabetes.

Some need up to five insulin shots a day to manage their
condition, said Dr Russell-Jones.

"It is only a matter of time before we enter the marketplace with
our insulin in a tablet, and we believe that most people prefer to take a
tablet instead of an injection," he added.

BACKGROUND
**********

Apollo Life Sciences was listed on the Australian Stock Exchange
on June 29, 2005.

The company focused on developing and commercialising human
proteins for treatment of disease and ageing.

It also has a number of therapeutic products currently in
development.

Apollo Life is developing therapeutics to combat such diseases as
Psoriasis, Hepatitis C, Multiple Sclerosis, Rheumatoid arthritis,
Alzheimer's, strokes and Stents.

It has also conducted preliminary work on proteins that target
Hepatitis B, HIV, Dementia, Parkinson's disease and certain types of
cancer.

Apollo is in the pre-clinical stages of testing products for hair
regrowth, hair removal and skin rejuvenation.

The company offers research reagents to scientists for pure and
applied biological experiments which it believes are are more suitable
for research because of their human-like properties.

[BrauchGeld]

Newsletter 30.März 2007
http://www.aspecthuntley.com.au/docserver/00707634.pdf?filei…


Insulin in a tablet Using its own technology, Oradel™, Apollo is developing a tablet form of insulin. Preclinical studies show it is now possible to have a long-acting tablet instead of needles. We show why we are confident the human trials will be successful. In experiments, Oradel™ insulin brings blood glucose levels into the normal range and holds them there for sustained periods of time, up to 24 hours.

[invest2002]

[BrauchGeld]

ASX/Media Announcement 1 June, 2007

Apollo advances IP position of Oradel technology

Australian bio-discovery company Apollo Life Sciences (ASX: AOP) today announced the successful filing of an international patent application (PCT application) in relation to its oral drug delivery platform. Oradel™ combines the ability to protect therapeutic proteins from harsh stomach enzymes and to actively promote transportation of such drugs into the bloodstream.
The PCT filing will assist Apollo in its ongoing discussions with a number of large global pharmaceutical companies in the development of specific applications of the Oradel™ technology. Follow-on national/regional phase patent applications in a range of key markets (including the US, EU countries, Australia, China, Japan, India) will provide protection until at least 2026 upon grant.
Key patentability features of the Oradel™ technology:
• Novel nanoparticle structures of a defined size distribution
• Novel three step method of nanoparticle production which is low cost and readily scalable
• Nanoparticles can be loaded with a range of pharmaceutical agents, including antibody-sized proteins
• Nanoparticles can be coated with any one of 5 distinct targeting moieties
• Demonstrable experimental evidence in relation to the treatment of diabetes and inflammation.
Additional patent applications covering new variants of the nanoparticle structure, methods of manufacture and improvements on related therapeutic applications will be filed over the next 6 months to take advantage of the “trade secret” period that exists prior to the publication of the PCT application.
By overcoming the obstacles of degradation and poor absorption, the Oradel™ delivery platform offers an alternative to injection for biopharmaceutical drugs that need to be repeatedly administered over a period of months or years. The first application, oral generic insulin for the $18 billion diabetes market, will enter clinical trials later this calendar year. This will be shortly followed by Oradel™ ALS-00T2 therapy for rheumatoid arthritis. Apollo’s proprietary anti-inflammatory TNF receptor protein, ALS-00T2, has shown strong preclinical results in animal models of inflammation. The worldwide market for anti-TNF proteins and antibodies such as ALS-00T2 is estimated at US$10 billion.

[ipollit]

Antwort auf Beitrag Nr.: 29.578.239 von BrauchGeld am 01.06.07 18:01:05

extrem schnell wirksames Insulin und orales Insulin...

wen es interessiert... etwas seriöser dürften da wohl Biodel (BIOD) sein, die letztens ihr IPO an der Nasdaq hatten...



mfg ipollit

[BrauchGeld]

350 mio$ marktkap für so eine schwache pipeline ? da ist ja meine Apollo viel günstiger und besser .

[BrauchGeld]

Auch wenn der kurs im moment nicht ganz so mitspielt halte ich Apollo Life für eine gigantische story.

http://bulletin.ninemsn.com.au/article.aspx?id=272579

Monday, June 18, 2007
A new insulin tablet offers hope for an end to daily injections. By Katherine Fleming.

Putting an end to injections is one of the great aims of diabetes research, and biotech companies are scrambling to tap into a market worth billions of dollars. An insulin tablet that could potentially revolutionise treatment is scheduled to begin human trials in Australia later this year, testing technology developed by Sydney-based Apollo Life Sciences to overcome hurdles that currently require insulin to be injected.

More than 140,000 people in Australia have Type 1 diabetes (formerly called juvenile diabetes) and need up to four injections of insulin daily because their bodies don't produce it. Type 2 diabetes affects 900,000 Australians (about half undiagnosed). It can often be managed with weight loss and lifestyle changes, although insulin injections are required for some.

Apollo is one of several companies around the world developing oral insulin products to replace needles. Sprays and powders that can be absorbed through the lungs or walls of the cheeks are being tested overseas, but Apollo is keen to pursue an insulin tablet, which patients may find preferable. The tablet needs to beat two key barriers: insulin is destroyed by acids in the stomach unless protected, but any protective shield hampers its absorption into the bloodstream through the gut wall.

This month, Apollo filed a patent application for its Oradel technology, which it believes will solve both problems. The insulin is encapsulated in a tiny "transporter molecule" to protect it, which is then coated with a vitamin. Vitamins are naturally pulled through the stomach wall into the bloodstream, taking the molecule through as well. It then breaks down, releasing the insulin.

Apollo chief executive John Priest - former Coca-Cola Amatil chief financial officer and corporate development director - says the technology has been impressive in animal tests. "In our pre-clinical studies, the oral insulin has performed exceedingly well. It has taken insulin down to normal levels in diabetic animals and been able to hold it there for eight to 24 hours," Priest says. "The end result of that is a tablet a day."

Apollo has appointed three experts from the International Diabetes Institute to an advisory committee: Professor Paul Zimmet, Associate Professor Jonathan Shaw and Dr Matthew Cohen. Zimmet says the very early data indicates Apollo's method is one of the best prospects for developing oral insulin.

Dr Neville Howard, president of Diabetes Australia (NSW), says diabetics and doctors will welcome oral insulin but warns it has proven difficult to develop. "[Researchers] have been trying to develop oral insulin for a long time and most have fallen over because insulin is unique in hormones; the dosage has to be very precise," he says.

"Too much is dangerous and too little doesn't work. That has been a problem for at least two decades for researchers trying to get oral insulin."

Professor Lesley Campbell, a clinician and diabetes researcher at the Garvan Institute, agrees a tablet may not be sophisticated enough to get dosages and regulation of insulin right, for example after meals. "Regulation of insulin therapy is the real challenge," she says.

If those barriers can be overcome, the financial returns are likely to be substantial. "Currently, for all diabetes and for all treatments, the market is around $US18bn a year annually and it's growing at 40% per annum, which is a bit staggering really," says Priest. "Doctors are loathe to prescribe and people are loathe to use needles and so tend not to control their diabetes as well as they might. This will take that problem away."

While newer insulin products are used for injection, Priest says older versions of insulin can be used for the tablets, making it "cheap and easy and scalable to make".

Apollo plans to use the Oradel technology in trials of its anti-inflammatory therapy, which it hopes can replace injections for serious cases of conditions including arthritis and Crohn's disease. It's also working on ways to have molecules absorbed through the skin. This year, it announced it had successfully vaccinated mice against tetanus this way.

The insulin tablets will be the first of Apollo's drugs to go into clinical trials. Priest expects to reach phase two in the next 18 months; faster than a typical trial because the delivery system, not the drug, is being tested. Apollo will then seek a development partner for larger, more expensive trials.